Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.1

STANDARD TREATMENT — Topical corticosteroids are generally recommended for initial treatment of mild to moderate plaque psoriasis. The topical retinoid tazarotene (Tazorac, and others) and topical vitamin D analogs such as calcipotriene (Dovonex, and others) can also be used, alone or in combination with topical corticosteroids. For patients with moderate to severe disease, systemic treatment options include biologics, the oral phosphodiesterase type-4 inhibitor apremilast ... more      

Would you like to read the rest of this article?  Gain access below.